Radijum-223 hlorid
Radijum-223 hlorid je izotop radijuma sa 11,4-dana dugim poluživotom, u kontrastu sa uobičajenim izotopom radijum-226, čiji poluživot je 1601 godina. Glavna primena radijuma-223 je kao radiofarmaceutik za tretiranje metastatičkih kancera kostiju. Ovaj oblik primene se bazira na njegovoj hemijskoj sličnosti sa kalcijumom, i kratkim opsegom njegove alfa radijacije.[1][2][3][4][5]
| Klinički podaci | |
|---|---|
| Robne marke | Alpharadin, Xofigo |
| AHFS/Drugs.com | chloride.html Monografija |
| Identifikatori | |
| CAS broj | 444811-40-9 |
| ATC kod | nije dodeljen |
| DrugBank | DB08913 |
| UNII | RJ00KV3VTG 
|
| ChEBI | CHEBI:74895
|
| Hemijski podaci | |
| Formula | 223RaCl2 |
| Mol. masa | 296,91 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 11,4 dana |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Reference
uredi- ↑ Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Kakonen SM, Scholz A: Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16. PMID 23682134
- ↑ Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94. PMID 17544845
- ↑ Bruland OS, Nilsson S, Fisher DR, Larsen RH: High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. PMID 17062709
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura
uredi- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
